Advertisement
Advertisement
LYEL
Lyell Immunopharma, Inc. Common Stock
20.18
USDSponsored
+0.04
+0.19%
Mar 26, 15:59 UTC -4
Closed
After-Market
20.20
+0.02
+0.08%
LYEL Earnings Reports
Positive Surprise Ratio
LYEL beat 14 of 19 last estimates.
74%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$9.69K
/-$2.26
Implied change from Q4 25 (Revenue/ EPS)
+61.50%
/-69.87%
Implied change from Q1 25 (Revenue/ EPS)
+38.43%
/-36.16%
Lyell Immunopharma, Inc. Common Stock earnings per share and revenue
On Mar 12, 2026, LYEL reported earnings of -7.50 USD per share (EPS) for Q4 25, missing the estimate of -2.27 USD, resulting in a -229.53% surprise. Revenue reached 6.00 thousand, compared to an expected 12.44 thousand, with a -51.78% difference. The market reacted with a +0.51% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -2.26 USD, with revenue projected to reach 9.69 thousand USD, implying an decrease of -69.87% EPS, and increase of 61.50% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Vivani Medical, Inc. Common Stock (DE)
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.09
Surprise
-
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were Lyell Immunopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Lyell Immunopharma, Inc. Common Stock reported EPS of -$7.50, missing estimates by -229.53%, and revenue of $6.00K, -51.78% below expectations.
How did the market react to Lyell Immunopharma, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 0.51%, changed from $25.50 before the earnings release to $25.63 the day after.
When is Lyell Immunopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Lyell Immunopharma, Inc. Common Stock's next earnings report?
Based on 4
analysts, Lyell Immunopharma, Inc. Common Stock is expected to report EPS of -$2.26 and revenue of $9.69K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement